Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leiomyosarcoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 165fludarabine phosphate 110Peripheral Blood Stem Cell Transplantation 94Mycophenolic Acid 88Whole-Body Irradiation 81Etoposide 81Tacrolimus 73Busulfan 68Melphalan 67Filgrastim 66fludarabine 62Radiotherapy 56Doxorubicin 54Cyclosporine 54Rituximab 50Brentuximab Vedotin 48Antilymphocyte Serum 47Granulocyte Colony-Stimulating Factor 42Vinblastine 41Methotrexate 38Dacarbazine 37Cytarabine 35Gemcitabine 34Nivolumab 30Bleomycin 29Carmustine 28Vincristine 25Prednisone 25Sirolimus 24Bendamustine Hydrochloride 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hodgkin Disease × mocetinostat × Clear all
NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
7 enrolled 10 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡